Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database
21 November 2023 - 7:30AM
Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to
ClinicalTrials.gov database
ORION CORPORATION INVESTOR NEWS 21 NOVEMBER 2023 at 08:30
EET Phase
3 Clinical Trials with ODM-208 (MK-5684) posted to
ClinicalTrials.gov database
Two new Phase 3 clinical trials to evaluate the safety and
efficacy of ODM-208 for the treatment of patients with metastatic
castration-resistant prostate cancer (mCRPC) have been posted to
the ClinicalTrials.gov website. The studies are not yet recruiting
patients.
Further information is available on ClinicalTrials.gov
- A study of MK-5684 Versus
Alternative Next-generation Hormonal Agent (NHA) in Metastatic
Castration-resistant Prostate Cancer (mCRPC) Post One NHA (study
identifier: NCT06136650)
- A study of MK-5684 Versus
Alternative NHA in mCRPC (study indentifier: NCT06136624)
About ODM-208/MK-5684
ODM-208 (or MK-5684) is an investigational oral, non-steroidal
and selective inhibitor of the CYP11A1 enzyme discovered and
developed by Orion for the treatment of hormone-dependent cancers,
such as prostate cancer. ODM-208 is being developed through a
collaboration with MSD (tradename of Merck & Co., Inc. Rahway
NJ
USA).
Contact person:Tuukka Hirvonen, Investor
RelationsOrion Corporationtel. +358 10 426 2721e-mail:
tuukka.hirvonen@orion.fi
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and self-care products. The core therapy areas of our
pharmaceutical R&D are oncology and pain. Proprietary products
developed by Orion are used to treat cancer, neurological diseases
and respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Orion (BIT:1ORNBV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024